Grade Purity, Third-Party Testing, and Mitochondrial Support Claims Are Reshaping Consumer Evaluation Standards for Methylene ...
Breakthrough Therapy Designation request has been submitted to FDA Company to request a Type B meeting with FDA in early 2026 to discuss requirements for a supplementary New Drug Application (sNDA) ...
Warnings and Precautions Hemolytic Anemia: G6PD testing must be performed before prescribing ARAKODA ® due to the risk of hemolytic anemia. Monitor patients for signs or symptoms of hemolysis. G6PD ...
Company engaged patients diagnosed with chronic babesiosis via social media in a nationwide naming competition A $5K donation from the Company was split between ILADEF and GLA to recognize the winning ...
New Drug Application intended for 2026, subject to generation of positive data from three U.S. clinical trials planned or in progress Total addressable market (TAM) for ARAKODA for Human Babesiosis is ...
The declining efficacy and widespread resistance to antimalarial drugs (AMD) pose significant challenges to global malaria control and elimination efforts. To enhance treatment efficacy, the World ...
New 8-count bottles now available through major retail pharmacies ARAKODA® is the only weekly prophylactic therapy to provide protection against the blood and liver stages of malaria WASHINGTON, June ...
WASHINGTON, D.C., April 08, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ("60 Degrees" or the "Company"), a pharmaceutical company focused on developing new ...
Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Differentiating the cause ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback